AACR-GlaxoSmithKline Outstanding Clinical Scholar Awards are presented to promising young cancer researchers who are the first authors and presenters of highly meritorious abstracts related to clinical cancer research. These Awards provide a $4,000 travel grant to be spent over two years to support the Scholar's attendance at the AACR 101st Annual Meeting 2010 and future AACR meetings and conferences.
Eligibility
- Graduate students, medical students and residents, clinical fellows or equivalent, and postdoctoral fellows who are traveling from any country in the world are eligible.
- Applicants must be the first author and presenter of an abstract in clinical cancer research. For the purposes of this Award, clinical cancer research is defined as research involving human subjects or tissue/samples from human subjects. Cell lines, animal models, or other laboratory research will not be considered.
- Candidates must be AACR members. Nonmembers must complete an application for Associate Membership prior to the abstract submission deadline to be considered.
- Employees or subcontractors of industry are not eligible.
Application
Eligible individuals should check the appropriate box in the Online Abstract Submission System and must submit their abstracts by the December 1, 2009, deadline. A letter of support (no more than one page) must be sent from the applicant's mentor, supervisor, or department head to elizabeth.martin@aacr.org by December 1, 2009. The letter should confirm that the applicant meets the eligibility requirements; describe the applicant's clinical cancer research to be presented at the Annual Meeting; and attest that the mentor, supervisor, or department head will permit the applicant to attend future AACR meetings or conferences to be supported by this Award.
Selection and Notification
Selection is made by the Program Committee based upon the novelty, quality, and significance of the abstract submitted. Recipients of AACR-GlaxoSmithKline Clinical Scholar Awards will receive notification separate from abstract acceptance and scheduling information. Due to the number of applications for these Awards, only the recipients will be notified. Names of the Award recipients will be posted on the AACR website and in the Annual Meeting Program.
Note: Presenting at a poster session or minisymposium does not guarantee that the applicant will receive an AACR-GlaxoSmithKline Clinical Scholar Award; however, minisymposium presenters will be favored during the selection process.
Support
The AACR-GlaxoSmithKline Clinical Scholar Awards provide a travel grant of $4,000 to be spent over two years in support of the Scholar's participation and presentation of data at the AACR 101st Annual Meeting 2010 and future AACR meetings and conferences.
Up to $2,000 per meeting may be used, and reimbursement checks are provided after the meeting or conference upon submission of proper documentation of travel, housing, registration, and/or subsistence expenses.
Award recipients are required to pay the Annual Meeting registration fee and make their own travel and housing arrangements. Therefore, all applicants are encouraged to register immediately to take advantage of the reduced advance registration rates. Booking travel and housing early will also ensure that the lowest rates will be available.
If an Award recipient is unable to attend the Annual Meeting or will not be the presenter of the abstract, the Award must be forfeited. Awards are not transferable.
SPOTLIGHT
2009 AACR-GlaxoSmithKline Outstanding Clinical Scholars
Mark M. Aloysius, M.B.B.S., University of Nottingham, United Kingdom, Generation in vivo of enhanced of human telomerase reverse transcriptase (hTERT) peptide (p540 or p865) specific CD8+ T cell response is best achieved by vaccination with peptide-pulsed dendritic cells (DCs) activated and matured in vitro with TNF-α but l.
Uchechi Anyanwu, B.S., Penn State University, PA, Elevated pretreatment serum TIMP-1 level predicts reduced PFS and overall survival in trastuzumab-treated metastatic breast cancer patients.
Gerhardt Attard, M.D., Institute of Cancer Research and the Royal Marsden NHS Foundation Trust, United Kingdom, Molecular characterization of circulating tumor cells (CTC) from castration-resistant prostate cancer (CRPC) patients (pts) treated with abiraterone acetate (AA).
Sheetal V Bajaj, M.D., Childrens Hospital Los Angeles, CA, Identification of a putative biomarker that uniquely characterizes translocation-positive alveolar rhabdomyosarcomas.
Jayshree L. Hirpara, M.B.B.S., National University of Singapore, Singapore, Mislocalization of Apaf-1 as a mechanism of drug resistance in B-cell lymphoma.
Jose A. Karam, M.D., UT Southwestern Medical Center, TX, Prognostic value of Survivin in patients with bladder cancer.
Jung Eun Lee, Sc.D., Brigham and Women's Hospital and Harvard Medical School, MA, Folate intake and the risk of colorectal cancer and adenoma in two large prospective studies: modification by time.
Anne Marie McKnight, B.S., Johns Hopkins School of Public Health, MD, Racial and socioeconomic disparities in cervical cancer mortality in New York City, 1995-2006.
Rohit Mehra, M.D., University of Michigan, MI, The role of TMPRSS2: Ets gene fusions in androgen independent metastatic prostate cancers.
Anirban P. Mitra, M.D., University of Southern California Keck School of Medicine, CA, Associations of smoking and non-steroidal anti-inflammatory drug use with molecular alterations in urinary bladder cancer.
Mahsa Mohebtash, M.D., National Cancer Institute, MD, Clinical outcomes following immunotherapy with a MUC1/CEA vaccine in patients with metastatic breast and ovarian cancer.
Alexei Morozov, M.D., Ph.D., Memorial Sloan-Kettering Cancer Center, NY, Mesenchymal stem cell features of sarcoma cell lines and primary cultuResearch
Leon Raskin, Ph.D., University of Michigan, MI, HMGA2 is a novel prognostic factor in melanoma.
April A. N. Rose, B.S., McGill University, Canada, Translational relevance for ADAM-10 mediated shedding of GPNMB/Osteoactivin, a novel mediator of recurrence in triple negative breast cancers.
Gerald Y. Tan, M.D., Weill Medical College of Cornell University, NY, Multiphoton microscopy imaging of periprostatic architecture from fresh human prostatectomy specimens: Promising potential for improving cancer clearance and potency outcomes during nerve-sparing radical prostatectomy.
Tonya C. Walser, Ph.D., David Geffen School of Medicine at University of California Los Angeles, CA, Snail at the intersection of inflammation, EMT, and early lung cancer development: A possible marker of the field cancerization effect.
Lingzhi Zhang, Ph.D., University of California San Diego, CA, Expression of cyclic nucleotide phosphodiesterase 7B: a novel biomarker and prognostic indicator in chronic lymphocytic leukemia.
2008 AACR-GlaxoSmithKline Outstanding Clinical Scholars
Manisha Bhutani, M.D., UT M.D. Anderson Cancer Center, TX, Oral epithelium as a surrogate tissue for assessing smoking-induced molecular alterations in lungs.
David W. Cescon, M.D., Princess Margaret Hospital, University of Toronto, Canada, p53 Arg72Pro, MDM2 T309G and CCND1 G870A polymorphisms are not associated with susceptibility to esophageal adenocarcinoma.
Eva J. Christensen, B.S., Princess Margaret Hospital, University of Toronto, Canada, Novel biomarkers of radiotherapy response in prostate cancer: A pilot study to determine protein expression patterns in blood and urine during radiotherapy for localized prostate cancer.
John D. Gordan, Ph.D., University of Pennsylvania, PA, HIF-α expression defines two subtypes of VHL-deficient clear cell renal carcinoma: differential effects on c-Myc and DNA damage response.
Jozien Helleman, Ph.D., Erasmus MC, The Netherlands, Association of an extracellular matrix gene cluster with breast cancer prognosis and response to tamoxifen: possible implications for treatment.
Ilaria Iacobucci, Ph.D., "L. and A. Seràgnoli", Italy, The Bcr-Abl kinase promotes aberrant expression of spliced oncogenic Ikaros isoforms in Philadelphia (Ph) positive acute lymphoblastic leukaemia (ALL) patients treated with tyrosine kinase inhibitors.
Hitoshi Inoue, M.D., Ph.D., Johns Hopkins University, MD, Mapping of DNA methylation status of GSTP1 CpG island in human prostate tissue.
Ramasamy Jagadeeswaran, Ph.D., University of Chicago, IL, Paxillin and MET interactions promote lung cancer growth, invasion, and angiogenesis.
Thomas John, M.B.B.S., Melbourne Centre for Clinical Sciences, Ludwig Institute for Cancer Research, Australia, ECSA/DPPA2 is an immunogenic embryo-cancer antigen that is co-expressed with cancer-testis antigens in non-small-cell lung cancer.
Pawadee Lohavanichbutr, M.D., Fred Hutchinson Cancer Research Center, WA, Genome-wide gene expression profiles of HPV-posi
Teemu J. Murtola, M.D., University of Tampere, School of Public Health, Finland, Statins and prostate cancer mortality in the Finnish prostate cancer screening trial.
David Olmos, M.D., Ph.D., Royal Marsden NHS Trust, United Kingdom, Changes in circulating tumor cell (ctc) counts after therapy predict overall survival (os) in castration-resistant prostate cancer (crpc) and have potential utility as surrogates of outcome to accelerate drug approval.
Zeshaan A. Rasheed, M.D., Ph.D., Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, MD, The functional stem cell marker aldehyde dehydrogenase enhances pancreatic cancer stem cell isolation and correlates with clinical prognosis.
Michael Wittinger, M.S., Medical Universtity Vienna, Austria, HCRP1 contributes to degradation of activated EGFR, a mechanism highly relevant for ovarian cancer.
Kimio Yonesaka, M.D., Ph.D., Dana Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, MA, Presence of amphiregulin autocrine-loop predicts sensitivity of EGFR wild type cancers to gefitinib and cetuximab.